Literature DB >> 9091014

Antenatal serum screening for genital herpes: a study of knowledge and attitudes of women at a central London hospital.

B Vonau1, N Low-Beer, S E Barton, J R Smith.   

Abstract

OBJECTIVE: To evaluate the knowledge and attitudes of women regarding genital herpes and specifically serum screening for prevention of vertical transmission.
SETTING: Antenatal clinic at the Chelsea and Westminster Hospital, London. POPULATION: Randomly selected women at their first antenatal visit.
METHODS: A questionnaire focussing on the women's knowledge of, and their attitudes about, genital herpes was completed. The results were analysed using the Statistical Package for Social Sciences (SPSS).
RESULTS: One hundred women were surveyed over six weeks. The majority (80%) were aware that genital herpes was a sexually transmitted disease and 60% were aware that it can be transmitted to the baby in pregnancy. Only 34% thought that genital herpes is always symptomatic and 56% believed that they would know for certain if they had herpes. Sixty percent thought they would know whether their partners had ever been infected. Eighty percent of our sample population were prepared to be screened, and 76% would also encourage their sexual partner to have a blood test.
CONCLUSION: This study shows that the study population had a good knowledge about genital herpes and that there would be acceptance of antenatal testing. Whether serum screening is cost-effective must still be evaluated. The impact of such a screening on a couple's relationship is potentially deleterious and needs to be assessed carefully before a screening programme for genital herpes is actually introduced. The next phase of our study will address this issue.

Entities:  

Mesh:

Year:  1997        PMID: 9091014     DOI: 10.1111/j.1471-0528.1997.tb11466.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  8 in total

1.  Neonatal herpes prevention: a minor public health problem in some communities.

Authors:  A Mindel; J Taylor; R L Tideman; C Seifert; G Berry; K Wagner; J Page; C Marks; B Trudinger; A Cunningham
Journal:  Sex Transm Infect       Date:  2000-08       Impact factor: 3.519

2.  Herpes simplex virus 2 infection rate and necessity of screening during pregnancy: a clinical and seroepidemiologic study.

Authors:  Il Dong Kim; Ho Sun Chang; Kyung Jin Hwang
Journal:  Yonsei Med J       Date:  2012-03       Impact factor: 2.759

3.  A prospective cohort study of partner testing for herpes simplex virus and sexual behavior during pregnancy.

Authors:  Shani Delaney; Carolyn Gardella; Constance Daruthayan; Misty Saracino; Linda Drolette; Lawrence Corey; Anna Wald
Journal:  J Infect Dis       Date:  2012-06-12       Impact factor: 5.226

4.  Genital herpes serotesting: a study of the epidemiology and patients' knowledge and attitude among STD clinic attenders in Coventry, UK.

Authors:  N Narouz; P S Allan; A H Wade; S Wagstaffe
Journal:  Sex Transm Infect       Date:  2003-02       Impact factor: 3.519

5.  The acceptance of HSV-testing partners of HSV-2 seronegative pregnant women.

Authors:  Carolyn Gardella; Elizabeth Krantz; Constance Daruthayan; Linda Drolette; Lawrence Corey; Anna Wald
Journal:  Sex Transm Dis       Date:  2009-04       Impact factor: 2.830

6.  The acceptability of the introduction of a type specific herpes antibody screening test into a genitourinary medicine clinic in the United Kingdom.

Authors:  H M Mullan; P E Munday
Journal:  Sex Transm Infect       Date:  2003-04       Impact factor: 3.519

7.  HSV serologic testing for pregnant women: willingness to be tested and factors affecting testing.

Authors:  David A Baker; Andrea Pressley; Lillian Meek; Reinaldo Figueroa; Barbara Yates; Lynn Dix
Journal:  Infect Dis Obstet Gynecol       Date:  2011-04-10

8.  Invasive Obstetric Procedures and Cesarean Sections in Women With Known Herpes Simplex Virus Status During Pregnancy.

Authors:  Helen C Stankiewicz Karita; Nicholas J Moss; Ellen Laschansky; Linda Drolette; Amalia S Magaret; Stacey Selke; Carolyn Gardella; Anna Wald
Journal:  Open Forum Infect Dis       Date:  2017-11-06       Impact factor: 3.835

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.